



Targeted Therapies and Druggable Genetic Anomalies in Acute Myeloid Leukemia (AML): From Diagnostic Tools to Therapeutic Interventions

Guest Editors:

Prof. Dr. Francesco Lanza

Hematology Unit and Romagna Transplant Network, Ravenna Hospital, University of Bologna, 48121 Ravenna, Italy

Prof. Dr. Ali Bazarbachi

Department of Internal Medicine, American University of Beirut, Medical Center, Beirut, Lebanon

Deadline for manuscript submissions:

closed (15 December 2021)

Message from the Guest Editors

Dear Colleagues,

Acute myeloid leukemia (AML) is a clonal disorder resulting from acquired somatic mutations in hematopoietic progenitor cells that lead to the dysregulation of differentiation and the proliferation of hematopoietic cells. An increasing understanding of the molecular aberrations that trigger the development of AML and the growing use of next generation sequencing are advancing the development of investigational drugs targeting driver genetic mutations. As a consequence, we believe that identifying “druggable” mutations paves the way for the use of novel targeted therapies.

This Special Issue will focus on novel diagnostic and therapeutic tools for the management of AML. The role of minimal residual disease detection for more intelligent management of acute leukemia will also be considered, provided that authors include a clinical setting in which one or more drugs targeting specific molecular abnormalities is presented.

To this end, *Cancers* is bringing together articles dealing with NGS data and the use of targeted therapies with the aim of improving our knowledge in the field of AML.

Prof. Dr. Francesco Lanza
Prof. Dr. Ali Bazarbachi





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)